ReviewFrontiers in oncology2022
Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche.
Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 4 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Real-world incidence of severe infections in multiple myeloma patients receiving bispecific antibodies: a meta-analysis.Annals of hematology · 2026Pooled it
- Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis.Annals of medicine · 2025Pooled it
- The addition of CD38 monoclonal antibody to triplet regimens improves survival in newly diagnosed multiple myeloma with high-risk cytogenetics: a systematic review and meta-analysis of randomized controlled trials.Frontiers in immunology · 2025Pooled it
- Efficacy, safety and economy of denosumab and zoledronic acid in the treatment of bone metastases of solid tumors and multiple myeloma: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Junctional Adhesion Molecule-A (JAM-A) Associates With High-Risk Disease in Multiple Myeloma Patients and a Structure-Based Rationally-Designed Peptide Inhibitor Attenuates Tumorigenic Features In Vitro and In Vivo.European journal of haematology · 2026Article
- Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma.The FEBS journal · 2026Review
- 3D biomimetic microgel platform for multiple myeloma: Approaching tumor microenvironment on cell lines and patient-derived cells.Materials today. Bio · 2026Article
- Drug Resistance in Multiple Myeloma: Tumor-Intrinsic Mechanisms and the Bone Marrow Microenvironment.Cell biochemistry and function · 2026Review
- Mechanistic Interplay Between Multiple Myeloma and Severe SARS-CoV-2 Infection: Therapeutic Promise of Mesenchymal Stem Cell-Derived Extracellular Vesicles.Biomedicines · 2026Review
- Genetic architecture of multiple myeloma: From somatic alterations to germline susceptibility and clinical implications.Translational oncology · 2026Review
- Programmed cell death protein 1 (PD-1) / programmed cell death ligand 1 (PD-L1) in multiple myeloma.Journal of the Egyptian National Cancer Institute · 2026Observational
- Defining the biological boundaries of daratumumab monotherapy: long-term insights from the CENTAURUS trial in high-risk smoldering multiple myeloma.Translational cancer research · 2026Article
- Evaluation of TIE-2 levels in newly diagnosed and untreated multiple myeloma patients.BMC cancer · 2026Article
- Molecular mechanisms underlying liposarcoma subtype transition and proteasome-associated targeted interventions.Journal of translational medicine · 2026Review
- Diagnostic and potential prognostic associations of long noncoding RNAs LIFR-AS1 and SLCO4A1-AS1 in multiple myeloma.Scientific reports · 2026Article
- Electrorotation as a tool for the dielectric characterization of tumor plasma cells in multiple myeloma.Scientific reports · 2026Article
- The Role of CD56 as an Immunophenotypic Marker in the Clinical Course of Multiple Myeloma.Journal of clinical medicine · 2026Article
- Targeting the immunological synapse in multiple myeloma.Discover oncology · 2026Review
- Prognostic value of the neutrophil-to-lymphocyte ratio in POEMS syndrome.Clinical and experimental medicine · 2026Article
- Genomic profiling enables personalized strategies to overcome drug resistance in multiple myeloma.Discover oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is still an incurable disease, despite considerable improvements in treatment strategies, as resistance to most currently available agents is not uncommon. In this study, data on drug resistance in MM were analyzed and led to the following conclusions: resistance occurs
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.